Bio-Techne

366 articles about Bio-Techne

• EXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TEST

  5/18/2023

  Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a previously published prospective, randomized study more than 1,000 patients aimed at evaluating the clinical utility of the ExoDx™ Prostate Test over a 5-year follow-up period.

• Bio-Techne Commercializes RNAscope Spatial Biology Workflow for the Standard Biotools Hyperion Imaging System

  5/16/2023

  Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities announced the expansion of the Advanced Cell Diagnostics -branded RNAscope™ in situ hybridization portfolio with the release of a RNAscope multiomic workflow for the Standard BioTools Hyperion™ Imaging System.

• Bio-Techne to Present at the 2023 RBC Capital Markets Global Healthcare Conference

  5/12/2023

  Bio-Techne Corporation announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 2:35 p.m. EDT.

• Cellular Origins Partners With ScaleReady to Simplify, Standardise, and Automate Cell Therapy Manufacturing

  5/11/2023

  Cellular Origins, a TTP Company focused on enabling scalable, cost-effective and efficient manufacture of cell and gene therapies (CGTs), has today announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together process development expertise, tools and technologies for scalable CGT manufacturing.

• Bio-Techne Announces Launch of Kappa and Lambda RNAscope ISH Probes as Analyte Specific Reagents (ASRs) for the Detection of Immunoglobulin Kappa and Lambda Light Chains mRNA

  5/10/2023

  Bio-Techne announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents for the detection of immunoglobulin kappa and lambda light chains mRNA in B-cells.

• Bio-Techne Releases Third Quarter Fiscal 2023 Results

  5/3/2023

  Bio-Techne Corporation reported its financial results for the third quarter ended March 31, 2023.

• Bio-Techne Declares Dividend - May 03, 2023

  5/3/2023

  Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2023.

• BIO-TECHNE TO PRESENT AT THE BofA SECURITIES 2023 HEALTH CARE CONFERENCE

  5/2/2023

  Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 , at 1:40 p.m. PDT.

• BIO-TECHNE AND LUNAPHORE ESTABLISH STRATEGIC PARTNERSHIP TO DEVELOP THE FIRST FULLY AUTOMATED SAME-SLIDE SPATIAL MULTIOMICS SOLUTION

  4/17/2023

  Bio-Techne (NASDAQ: TECH) and Lunaphore today announced a strategic partnership to develop the first fully automated spatial multiomics workflow with same-slide hyperplex detection of protein and RNA biomarkers.

• BIO-TECHNE TO SHOWCASE INNOVATIVE CANCER RESEARCH, CELL THERAPY AND MANUFACTURING TOOLS AT AACR 2023 CONFERENCE

  4/13/2023

  Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida.

• BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 3, 2023, TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

  4/12/2023

   Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 3, 2023 , at 8:00 a.m. CDT to review third quarter 2023 financial results.

• Bio-Techne Celebrates Milestone With More Than 1,000 Ella™ Instruments Now in Operation

  4/5/2023

  Bio-Techne Corporation announced it that it has reached a significant milestone with more than 1,000 Ella™ automated immunoassay instruments now in the field.

• Bio-Techne Completes Investment in Wilson Wolf Manufacturing

  4/3/2023

  Bio-Techne Corporation announced it has completed its investment in Wilson Wolf Manufacturing.

• BIO-TECHNE ANNOUNCES COMPLETION OF CELL AND GENE THERAPY CATAPULT PROCESS ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

  3/15/2023

  Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities.

• BIO-TECHNE TO PRESENT AT THE BARCLAYS GLOBAL HEALTHCARE CONFERENCE - March 10, 2023

  3/10/2023

  Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023, at 2:35 p.m. EDT.

• Bio-Techne Announces Investment in Wilson Wolf

  3/1/2023

  Bio-Techne Corporation announced Wilson Wolf Manufacturing has met the trailing 12-month earnings before interest, taxes, depreciation, and amortization target of $55 million, triggering Bio-Techne's initial investment in the company, which is expected to close at the end of March 2023.

• ExoDx Prostate Test Granted Expanded Coverage by Medicare

  2/24/2023

  Bio-Techne Corporation announced that a newly finalized local coverage determination from National Government Services, Inc., a Medicare Administrative Contractor, includes coverage for the ExoDx™ Prostate Test from Exosome Diagnostics, a Bio-Techne brand.

• BIO-TECHNE TO PRESENT AT THE CITI 2023 HEALTHCARE SERVICES, MEDTECH, TOOLS & HCIT CONFERENCE

  2/22/2023

  Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 , at 2:00 p.m. EST.

• Bio-Techne and Cell Signaling Technology Announce Partnership to Validate Simple Western Antibodies

  2/14/2023

  Bio-Techne Corporation and Cell Signaling Technology announced the addition of Simple Western™ validation to CST antibodies.

• Bio-Techne Releases Second Quarter Fiscal 2023 Results

  2/2/2023

  Bio-Techne Corporation reported its financial results for the second quarter ended December 31, 2022.